YednockTACannonCFritzLC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992; 356(6364): 63–66.
2.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
3.
KapposLO’ConnorPWPolmanCH, et al. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol2013; 260(5): 1388–1395.
4.
ButzkuevenHKapposLWiendlH, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry2020; 91(6): 660–668.
5.
WiendlHSpelmanTButzkuevenH, et al. Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Mult Scler2021; 27(5): 719–728.
6.
HoPRKoendgenHCampbellN, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. Lancet Neurol2017; 16(11): 925–933.
7.
McGuiganCCranerMGuadagnoJ, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J Neurol Neurosurg Psychiatry2016; 87(2): 117–125.
8.
MorrowSACliftFDevonshireV, et al. Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord2022; 65: 103995.
9.
ButzkuevenHKapposLSpelmanT, et al. No evidence for loss of natalizumab effectiveness with every-6-week dosing: A propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Ther Adv Neurol Disord2021; 14: 17562864211042458.
10.
FoleyJDeferGZhovtis RyersonL, et al. Primary results of NOVA: A randomized controlled study of the efficacy of 6 week dosing of natalizumab versus continued 4-week treatment for multiple sclerosis. Mult Scler Relat Disord2021; 59: 103626.
11.
Zhovtis RyersonLFoleyJChangI, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology2019; 93(15): e1452–e1462.
12.
DsilvaLMcCarthyKLyonsJ, et al. Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world. Expert Opin Drug Saf2023; 10: 995–1002.
